RAPT - RAPT Therapeutics, Inc.

58.02
0.040   0.069%

Share volume: 11,125,216
Last Updated: 03-02-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$57.98
0.04
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
14%
Profitability 2%
Dept financing 25%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0.43%
3 Months
66.06%
6 Months
336.90%
1 Year
5,322.43%
2 Year
538.99%
Key data
Stock price
$58.02
P/E Ratio 
0.00
DAY RANGE
$57.98 - $58.02
EPS 
-$13.80
52 WEEK RANGE
$0.71 - $58.02
52 WEEK CHANGE
$5,322.43
MARKET CAP 
426.510 M
YIELD 
N/A
SHARES OUTSTANDING 
27.711 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,349,476
AVERAGE 30 VOLUME 
$4,225,274
Company detail
CEO: Brian R. Wong
Region: US
Website: rapt.com
Employees: 80
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

RAPT Therapeutics, Inc. focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Recent news